These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 37480054)

  • 1. Role of microRNAs in regulation of doxorubicin and paclitaxel responses in lung tumor cells.
    Maharati A; Moghbeli M
    Cell Div; 2023 Jul; 18(1):11. PubMed ID: 37480054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of forkhead box proteins in regulation of doxorubicin and paclitaxel responses in tumor cells: A comprehensive review.
    Moghbeli M; Taghehchian N; Akhlaghipour I; Samsami Y; Maharati A
    Int J Biol Macromol; 2023 Sep; 248():125995. PubMed ID: 37499722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells.
    Zangouei AS; Alimardani M; Moghbeli M
    Cancer Cell Int; 2021 Apr; 21(1):213. PubMed ID: 33858435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced cell apoptosis triggered by a multi modal mesoporous amphiphilic drug delivery system.
    Pradhan L; Srivastava R; Bahadur D
    Nanotechnology; 2015 Nov; 26(47):475101. PubMed ID: 26526608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update.
    Torki Z; Ghavi D; Hashemi S; Rahmati Y; Rahmanpour D; Pornour M; Alivand MR
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):771-793. PubMed ID: 34510251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide analysis of miRNA signature differentially expressed in doxorubicin-resistant and parental human hepatocellular carcinoma cell lines.
    Zhang J; Wang Y; Zhen P; Luo X; Zhang C; Zhou L; Lu Y; Yang Y; Zhang W; Wan J
    PLoS One; 2013; 8(1):e54111. PubMed ID: 23359607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miRNAs as short non-coding RNAs in regulating doxorubicin resistance.
    Mirzaei S; Paskeh MDA; Moghadam FA; Entezari M; Koohpar ZK; Hejazi ES; Rezaei S; Kakavand A; Aboutalebi M; Zandieh MA; Rajabi R; Salimimoghadam S; Taheriazam A; Hashemi M; Samarghandian S
    J Cell Commun Signal; 2023 Dec; 17(4):1181-1202. PubMed ID: 38019354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNAs as the critical regulators of cisplatin resistance in gastric tumor cells.
    Zangouei AS; Moghbeli M
    Genes Environ; 2021 Jun; 43(1):21. PubMed ID: 34099061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells.
    Maharati A; Zanguei AS; Khalili-Tanha G; Moghbeli M
    Cell Commun Signal; 2022 Mar; 20(1):27. PubMed ID: 35264191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
    Lai J; Yang H; Zhu Y; Ruan M; Huang Y; Zhang Q
    BMC Cancer; 2019 Jun; 19(1):602. PubMed ID: 31215481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the long non-coding RNAs in regulation of Gemcitabine response in tumor cells.
    Maharati A; Samsami Y; Latifi H; Tolue Ghasaban F; Moghbeli M
    Cancer Cell Int; 2023 Aug; 23(1):168. PubMed ID: 37580768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNAs as the critical regulators of autophagy-mediated cisplatin response in tumor cells.
    Tolue Ghasaban F; Maharati A; Akhlaghipour I; Moghbeli M
    Cancer Cell Int; 2023 Apr; 23(1):80. PubMed ID: 37098542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells.
    Khalili-Tanha G; Moghbeli M
    Cell Mol Biol Lett; 2021 Aug; 26(1):39. PubMed ID: 34425750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-520c-3p Modulates Doxorubicin-Chemosensitivity in HepG2 Cells.
    Ragheb MA; Soliman MH; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
    Anticancer Agents Med Chem; 2021; 21(2):237-245. PubMed ID: 32357822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-451a attenuates doxorubicin resistance in lung cancer via suppressing epithelialmesenchymal transition (EMT) through targeting c-Myc.
    Tao L; Shu-Ling W; Jing-Bo H; Ying Z; Rong H; Xiang-Qun L; Wen-Jie C; Lin-Fu Z
    Biomed Pharmacother; 2020 May; 125():109962. PubMed ID: 32106373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low‑intensity ultrasound enhances the antitumor effects of doxorubicin on hepatocellular carcinoma cells through the ROS‑miR‑21‑PTEN axis.
    Xia C; Zeng H; Zheng Y
    Mol Med Rep; 2020 Mar; 21(3):989-998. PubMed ID: 32016465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
    Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
    Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.
    Kovalchuk O; Filkowski J; Meservy J; Ilnytskyy Y; Tryndyak VP; Chekhun VF; Pogribny IP
    Mol Cancer Ther; 2008 Jul; 7(7):2152-9. PubMed ID: 18645025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via up-regulation of PTEN in colon cancer cells.
    Shi X; Valizadeh A; Mir SM; Asemi Z; Karimian A; Majidina M; Safa A; Yosefi B
    Eur J Pharmacol; 2020 Aug; 880():173138. PubMed ID: 32416187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A.
    Zhang Y; He Y; Lu LL; Zhou ZY; Wan NB; Li GP; He X; Deng HW
    Kaohsiung J Med Sci; 2019 Jan; 35(1):17-23. PubMed ID: 30844143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.